TITLE

The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health

AUTHOR(S)
Oben, Julius; Enonchong, Ebangha; Kuate, Dieudonne; Mbanya, Dora; Thomas, Tiffany C.; Hildreth, DeWall J.; Ingolia, Thomas D.; Tempesta, Michael S.
PUB. DATE
January 2007
SOURCE
Lipids in Health & Disease;2007, Vol. 6, p20
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Metabolic Syndrome, or Syndrome X, is characterized by a set of metabolic and lipid imbalances that greatly increases the risk of developing diabetes and cardiovascular disease. The syndrome is highly prevalent in the United States and worldwide, and treatments are in high demand. ProAlgaZyme, a novel and proprietary freshwater algae infusion in purified water, has been the subject of several animal studies and has demonstrated low toxicity even with chronic administration at elevated doses. The infusion has been used historically for the treatment of several inflammatory and immune disorders in humans and is considered well-tolerated. Here, the infusion is evaluated for its effects on the cardiovascular risk factors present in metabolic syndrome in a randomized double-blind placebo-controlled study involving 60 overweight and obese persons, ages 25-60. All participants received four daily oral doses (1 fl oz) of ProAlgaZyme (N = 22) or water placebo (N = 30) for a total of 10 weeks, and were encouraged to maintain their normal levels of physical activity. Blood sampling and anthropometric measurements were taken at the beginning of the study period and after 4, 8 and 10 weeks of treatment. Eight participants did not complete the study. Results: ProAlgaZyme brought about statistically significant (p < 0.001) reductions in the following: weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein and fasting blood glucose levels, accompanied by a significant (p < 0.001) increase in HDL-cholesterol levels over the 10-week study period. The infusion was well-tolerated and no side effects were noted. Conclusion: ProAlgaZyme (4 fl oz daily) consumption resulted in significant reductions in weight and blood glucose levels, while significantly improving serum lipid profiles and reducing markers of inflammation, thus improving cardiovascular risk factors in overweight and obese subjects over a course of 10 weeks with an absence of adverse side effects.
ACCESSION #
30094313

 

Related Articles

  • DETECTING AND MANAGING METABOLIC SYNDROME: A FEASIBILITY STUDY IN A GENERAL MEDICINE CLINIC. De la Rosa, Alexandra; Tahsin, Bettina; Sanghani, Roshani; Pikelny, Iry; Fogelfeld, Leon; Stroger Jr., John H. // Ethnicity & Disease;Spring2008 Supplement1, Vol. 18, pS1:6 

    Metabolic syndrome is a constellation of risk factors associated with increased cardiovascular and diabetes risk. Clinical research indicates that lifestyle changes can dramatically modify and even reverse all factors of metabolic syndrome. This study examines the feasibility of lifestyle...

  • Coincident Linkage of Type 2 Diabetes, Metabolic Syndrome, and Measures of Cardiovascular Disease in a Genome Scan of the Diabetes Heart Study. Bowden, Donald W.; Rudock, Megan; Ziegler, Julie; Lehtinen, Allison B.; Xu, Jianzhao; Wagenknecht, Lynne E.; Herrington, David; Rich, Stephen S.; Freedman, Barry I.; Carr, J. Jeffrey; Langefeld, Carl D. // Diabetes;Jul2006, Vol. 55 Issue 7, p1985 

    Cardiovascular disease (CVD) is a major contributor to morbidity and mortality in type 2 diabetes, but the relationship between CVD and type 2 diabetes is not well understood. The Diabetes Heart Study is a study of type 2 diabetes-enriched families extensively phenotyped for measures of CVD,...

  • Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Tenenbaum, Alexander; Fisman, Enrique Z. // Cardiovascular Diabetology;2004, Vol. 3, p1 

    Although less clinical intervention studies have been performed with fibrates than with statins, there are evidences indicating that fibrates may reduce risk of cardiovascular events. The potential clinical benefit of the fenofibrate will be specified by the ongoing Fenofibrate Intervention and...

  • Commentary: Metabolic syndrome and mortality. Farmer, Andrew // BMJ: British Medical Journal (International Edition);4/15/2006, Vol. 332 Issue 7546, p882 

    The article explores the clinical value of diagnosing metabolic syndrome. Originally metabolic syndrome referred to a grouping of risk factors for cardiovascular disease. The article discusses how the majority of people with metabolic syndrome have insulin resistance, the syndrome's possible...

  • Metabolic Syndrome and Cardiovascular Mortality in Older Type 2 Diabetic Patients: A Longitudinal Study. Monami, Matteo; Lamanna, Caterina; Balzi, Daniela; Bartalucci, Francesca; Melani, Cecilia; Masotti, Giulio; Marchionni, NiccolĂ´; Mannucci, Edoardo // Journals of Gerontology Series A: Biological Sciences & Medical ;Jun2008, Vol. 63 Issue 6, p646 

    Background. Although age does not seem to modify the association of the metabolic syndrome (MS) with cardiovascular risk in middle-aged individuals, no comparison of risks associated with MS between old and middle-aged persons has been reported so far. Methods. An observational study was...

  • Prevalence and gender distribution of the metabolic syndrome. Ogbera, Anthonia O. // Diabetology & Metabolic Syndrome;2010, Vol. 2 Issue 1, p1 

    Background: The Metabolic syndrome (MetS) is a cardiovascular risk factor of public health significance and of recent has become a topical issue. The prevalence of diabetes mellitus (DM) is on the increase and with this scenario, a possible increase in burden of DM which may be largely...

  • Shorts. Klotter, Jule // Townsend Letter;May2007, Issue 286, p26 

    The article offers news briefs related to medicine in the U.S. Family doctors who care for 90% of the nation's diabetics are experiencing a difficult adjustment on medications and monitoring patients with several diseases. Metabolic syndrome is labeled for a group of measurements associated with...

  • Commentary. Sigal, Ronald J. // Evidence Based Medicine;Dec2005, Vol. 10 Issue 6, p172 

    The article comments on a study which showed that results for incidence of metabolic syndrome paralleled those for new onset diabetes, with intensive lifestyle intervention and metformin being more effective than placebo. Metabolic syndrome, as defined by the U.S. National Cholesterol Education...

  • Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial.  // Cardiovascular Diabetology;2011, Vol. 10 Issue 1, p102 

    The article presents a research which examines whether various metabolic syndrome (MS) components affects the risk of cardiovascular disease (CVD) equally or differently in type 2 diabetes patients with and without prior CVD and in predefined age and sex subgroups. It is reported that, the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics